FDA Offers Shortcut to Pharmaceutical Review Time
The FDA's newly announced Commissioner’s National Priority Voucher program will offer a 1-2 month review time to drug developers "supporting US national interests," the agency says.
The FDA's newly announced Commissioner’s National Priority Voucher program will offer a 1-2 month review time to drug developers "supporting US national interests," the agency says.
Under the most likely climate change scenarios, the societal burden of obstructive sleep apnea is expected to double in most countries over the next 75 years.
The Consumer Product Safety Commission will stop collecting data on injuries from adverse drug effects and other incidents like car accidents, according to a report from Reuters.
Exposure to lingering fine particulate matter (PM2.5) was associated with increased hospitalization risks for most cardiorespiratory diseases.
Understanding how to help asthma patients perform self-monitoring and self-management in the home is the key to provide quality, effective support.
A growing number of engineered stone countertop workers are developing silicosis, a preventable lung disease linked to high silica dust exposure.
The American public may lose the ability to comment on US Department of Health and Human Services policy decisions, as HHS secretary Robert F. Kennedy Jr. seeks an end to the practice that was established in 1971, according to Reuters.
Patients from low-income neighborhoods, those with Medicaid, and Black patients were less likely to receive ECMO than equally ill peers.